GDC-0941, 10 mg

STEMCELL Technologies supplies GDC-0941 (also known as Pictilisib) as a 10 mg vial of research-grade small molecule for oncology and signal transduction studies. This compound is a potent, selective, and orally bioavailable class I phosphatidylinositol 3-kinase (PI3K) inhibitor, targeting the p110α and p110δ catalytic subunits with IC50 values in the low nanomolar range (approximately 3 nM for PI3Kα and a similar value for PI3Kδ). Researchers deploy GDC-0941 to interrogate the PI3K/AKT/mTOR pathway in cancer cell lines, xenograft models, and primary tumor cultures, with peer-reviewed applications spanning HER2-amplified breast cancer, non-small cell lung cancer, and glioblastoma research.

The powder is packaged as a single-use vial intended for in vitro and in vivo work. Stock solutions are routinely prepared in DMSO at 10 to 20 mM and stored frozen at -20 °C, with protection from light recommended to preserve potency across repeated freeze-thaw cycles. The active chemical entity is 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, with a molecular weight near 513.6 g/mol and a free-base formulation suitable for cell-based kinase signaling assays and pharmacodynamic readouts.

This product is intended for research use only and is not approved for diagnostic or therapeutic applications in humans.